Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dixon, R. M.
Right arrow Articles by Smith, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dixon, R. M.
Right arrow Articles by Smith, A. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 125, No. 10, 2332-2341, October 2002
© 2002 Oxford University Press

Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease

Ruth M. Dixon1, Kevin M. Bradley2, Marc M. Budge2, Peter Styles1 and A. David Smith2

1 MRC Biochemical and Clinical Magnetic Resonance Unit, Department of Biochemistry, University of Oxford and 2 OPTIMA, Department of Pharmacology, University of Oxford and Radcliffe Infirmary, Oxford, UK

Correspondence to: R. M. Dixon, PhD, Department of Biochemistry, South Parks Road, Oxford OX1 3QU, UK E-mail: ruthd{at}bioch.ox.ac.uk

Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 x 15 x 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age-matched NINCDS-negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy- corrected hippocampal N-acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo-Inositol signals from these small voxels had poor signal-to-noise and demonstrated no significant changes. We conclude that 1HMRS-detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
T. Bartsch, K. Alfke, S. Wolff, A. Rohr, O. Jansen, and G. Deuschl
Focal MR spectroscopy of hippocampal CA-1 lesions in transient global amnesia
Neurology, March 25, 2008; 70(13): 1030 - 1035.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
A. J. Ross, P. S. Sachdev, W. Wen, and H. Brodaty
Longitudinal changes during aging using proton magnetic resonance spectroscopy.
J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2006; 61(3): 291 - 298.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
P. J. Modrego, N. Fayed, and M. A. Pina
Conversion From Mild Cognitive Impairment to Probable Alzheimer's Disease Predicted by Brain Magnetic Resonance Spectroscopy
Am J Psychiatry, April 1, 2005; 162(4): 667 - 675.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
H. Rusinek, Y. Endo, S. De Santi, D. Frid, W.-H. Tsui, S. Segal, A. Convit, and M. J. de Leon
Atrophy rate in medial temporal lobe during progression of Alzheimer disease
Neurology, December 28, 2004; 63(12): 2354 - 2359.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.